Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML

NCT01235572 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01235572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
July 31, 2014
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia